The document discusses the latest information on COVID-19 boosters and the global vaccination situation. It summarizes that natural infection provides lasting multi-faceted immunity while vaccines only induce antibody-based immunity. Current vaccines remain effective against severe disease for variants of concern. Booster doses are only recommended for some immunocompromised groups. There are concerns about inequitable global vaccine distribution and the potential for boosters to exacerbate this if administered widely in wealthy countries before access improves elsewhere.
Post vaccination -Multisystemic Inflammatory Syndrome -Adultskomalicarol
Multi-system inflammatory syndrome in adults
(MIS-A) is gaining recognition among adult physicians. MIS-A is
a rare but important syndrome that can be difficult to distinguish
from severe COVID-19. MIS- A can occur following vaccination
for SARS-CoV-2 is not reported till date.
Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring in US history. VITAS Healthcare offer an educational presentation for our partner organizations to use for their own in-house or staff training.
Post vaccination -Multisystemic Inflammatory Syndrome -Adultskomalicarol
Multi-system inflammatory syndrome in adults
(MIS-A) is gaining recognition among adult physicians. MIS-A is
a rare but important syndrome that can be difficult to distinguish
from severe COVID-19. MIS- A can occur following vaccination
for SARS-CoV-2 is not reported till date.
Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring in US history. VITAS Healthcare offer an educational presentation for our partner organizations to use for their own in-house or staff training.
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr. Rizah Mazzuin Razali, the head of Geriatric Unit and Internal Medicine Physician working in Kuala Lumpur Hospital, Ministry of Health Malaysia.
Mechanism of different types of vaccines in developmentEmilioMolina23
Recap of certain vaccines technologies against Covid-19
Introduce MOA of current and in development Covid-19 vaccines
Ever since the first vaccine was developed in 1796 to treat smallpox, several different methods have been created to develop successful vaccines. Today, those methods, known as vaccine technologies, are more advanced and use the latest technology to help protect the world from preventable diseases.
Depending on the pathogen (a bacteria or virus) that is being targeted, different vaccine technologies are used to generate an effective vaccine.
In total, there are five different vaccine technology platforms in this presentation each with its own benefits, and examples.
Journal club covid vaccine neurological complications ZIKRULLAH MALLICK
the risks of adverse neurological events following SARS-CoV-2 infection are much greater than those associated with vaccinations, highlighting the benefits of ongoing vaccination programs.
The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4] The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020.[5] As of 25 March, more than 422,000 cases of COVID-19 have been reported in more than 190 countries and territories, resulting in more than 18,900 deaths and more than 109,000 recoveries.
Die britische Regierung räumt ein, dass Impfstoffe das natürliche Immunsystem von Doppelgeimpften geschädigt haben. Die britische Regierung hat zugegeben, dass Sie nach einer Doppelimpfung nie wieder eine vollständige natürliche Immunität gegen Covid-Varianten – oder möglicherweise gegen andere Viren – erlangen können. Sehen wir also zu, wie die „echte“ Pandemie jetzt beginnt! In seinem „COVID-19 Vaccine Surveillance Report“ (Woche 42) räumt das britische Gesundheitsministerium auf Seite 23 ein, dass „die N-Antikörperspiegel bei Menschen, die sich nach zwei Impfdosen infizieren, niedriger zu sein scheinen“. Es heißt weiter, dass dieser Rückgang der Antikörper im Wesentlichen dauerhaft ist. Was bedeutet das? Wir wissen, dass Impfstoffe eine Infektion oder Übertragung des Virus nicht verhindern (tatsächlich zeigt der Bericht an anderer Stelle, dass geimpfte Erwachsene jetzt viel wahrscheinlicher infiziert werden als ungeimpfte). Die Briten stellen nun fest, dass der Impfstoff die Fähigkeit des Körpers beeinträchtigt, nach einer Infektion Antikörper zu bilden, nicht nur gegen das Spike-Protein, sondern auch gegen andere Teile des Virus. Insbesondere scheinen geimpfte Personen keine Antikörper gegen das Nukleokapsid-Protein, die Hülle des Virus, zu bilden, das ein entscheidender Teil der Reaktion bei ungeimpften Personen ist. Langfristig sind die Geimpften deutlich anfälliger für eventuelle Mutationen im Spike-Protein, auch wenn sie bereits einmal oder mehrmals infiziert und geheilt wurden. Die Ungeimpften hingegen werden eine dauerhafte, wenn nicht sogar dauerhafte Immunität gegen alle Stämme des angeblichen Virus erlangen, nachdem sie auch nur einmal auf natürliche Weise damit infiziert wurden. Quelle: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-report-week-42.pdf Die
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr. Rizah Mazzuin Razali, the head of Geriatric Unit and Internal Medicine Physician working in Kuala Lumpur Hospital, Ministry of Health Malaysia.
Mechanism of different types of vaccines in developmentEmilioMolina23
Recap of certain vaccines technologies against Covid-19
Introduce MOA of current and in development Covid-19 vaccines
Ever since the first vaccine was developed in 1796 to treat smallpox, several different methods have been created to develop successful vaccines. Today, those methods, known as vaccine technologies, are more advanced and use the latest technology to help protect the world from preventable diseases.
Depending on the pathogen (a bacteria or virus) that is being targeted, different vaccine technologies are used to generate an effective vaccine.
In total, there are five different vaccine technology platforms in this presentation each with its own benefits, and examples.
Journal club covid vaccine neurological complications ZIKRULLAH MALLICK
the risks of adverse neurological events following SARS-CoV-2 infection are much greater than those associated with vaccinations, highlighting the benefits of ongoing vaccination programs.
The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4] The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020.[5] As of 25 March, more than 422,000 cases of COVID-19 have been reported in more than 190 countries and territories, resulting in more than 18,900 deaths and more than 109,000 recoveries.
Die britische Regierung räumt ein, dass Impfstoffe das natürliche Immunsystem von Doppelgeimpften geschädigt haben. Die britische Regierung hat zugegeben, dass Sie nach einer Doppelimpfung nie wieder eine vollständige natürliche Immunität gegen Covid-Varianten – oder möglicherweise gegen andere Viren – erlangen können. Sehen wir also zu, wie die „echte“ Pandemie jetzt beginnt! In seinem „COVID-19 Vaccine Surveillance Report“ (Woche 42) räumt das britische Gesundheitsministerium auf Seite 23 ein, dass „die N-Antikörperspiegel bei Menschen, die sich nach zwei Impfdosen infizieren, niedriger zu sein scheinen“. Es heißt weiter, dass dieser Rückgang der Antikörper im Wesentlichen dauerhaft ist. Was bedeutet das? Wir wissen, dass Impfstoffe eine Infektion oder Übertragung des Virus nicht verhindern (tatsächlich zeigt der Bericht an anderer Stelle, dass geimpfte Erwachsene jetzt viel wahrscheinlicher infiziert werden als ungeimpfte). Die Briten stellen nun fest, dass der Impfstoff die Fähigkeit des Körpers beeinträchtigt, nach einer Infektion Antikörper zu bilden, nicht nur gegen das Spike-Protein, sondern auch gegen andere Teile des Virus. Insbesondere scheinen geimpfte Personen keine Antikörper gegen das Nukleokapsid-Protein, die Hülle des Virus, zu bilden, das ein entscheidender Teil der Reaktion bei ungeimpften Personen ist. Langfristig sind die Geimpften deutlich anfälliger für eventuelle Mutationen im Spike-Protein, auch wenn sie bereits einmal oder mehrmals infiziert und geheilt wurden. Die Ungeimpften hingegen werden eine dauerhafte, wenn nicht sogar dauerhafte Immunität gegen alle Stämme des angeblichen Virus erlangen, nachdem sie auch nur einmal auf natürliche Weise damit infiziert wurden. Quelle: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-report-week-42.pdf Die
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
1. THE LATEST ON THE COVID-19 GLOBAL SITUATION
& COVID-19 VACCINE BOOSTERS
CORONAVIRUS
UPDATE
66
An update on
COVID-19
vaccine booster doses
LAST UPDATE: 3 SEPTEMBER 2021
2. 2
* Data are incomplete for the current week. Cases depicted by bars; deaths depicted by line
Current global situation
CASES REPORTED TO WHO AS OF 3 September 2021
CHECK OUT THE LATEST
GLOBAL SITUATION
WHO
Coronavirus
Disease (COVID-19)
Dashboard
• Cases: > 218 million • Deaths: > 4.5 million
4. • lasts many months1,2
• is multi-faceted and generates antibodies against
the spike protein plus other non-structural
proteins (Nucleoprotein (N), Matrix protein (M),
Envelope protein (E))
• induces systemic immunity and mucosal immunity
4
Infection-induced immunity to COVID-19
https://www.bmj.com/content/373/bmj.n1605
https://www.nature.com/articles/s41586-021-03696-9
Infection-induced immunity to COVID-19:
5. • The immune system is the body’s natural ability to defend against pathogens (eg. viruses,
bacteria) and resist infections
• Two types of immunity are:
➢ innate immunity and
➢ adaptive immunity
5
Natural immune response to viral infections
Innate immune response
• First line of defence
• General immediate response to ANY infection
• The innate response activates the adaptive
immune response1
Adaptive immune response
• Second line of defence
• Specific response to the infection
• Starts after 6 - 8 days
• Involves two types of white blood cells
➢ T cells (cellular response)
➢ B cells (antibody response)
1 A ‘weaker’ innate response (e.g. in elderly people or those with underlying health problems) may result in delayed stimulation of
the adaptive response
6. • T cells recognize cells that are infected
with a specific virus and rapidly
increase in number to tackle the
infection
• Types of T cells:
➢ CD4+ helper T cells bring in other cells of
the immune system and stimulate B-cells
to produce antibodies specific to that
virus
➢ CD8+ cytotoxic T cells kill the cells in
which the virus is multiplying and help to
slow down or stop the infection
6
Adaptive immune response: T cells
T cells (cellular response)
https://www.virology.ws/2020/11/05/t-cell-responses-to-coronavirus-infection-are-complicated/
7. • B cells produce antibodies that are specific to the virus
• IgM antibodies are produced first and disappear after a few weeks
• IgG antibodies are produced at the same time or a couple days later, and titres (levels) usually
remain for months or years
• In addition, the mucosal immune system can produce IgA antibodies. This is called mucosal
immunity
• An infection with SARS-CoV-2 initially infects the upper respiratory tract which triggers the
production of IgA antibodies
7
Adaptive immune response: B cells
B cells (antibody response)
• Once the infection is over, the T cells and B cells decline in number, but some cells will remain (memory cells)
• Memory cells respond rapidly if they come in contact with the same virus again, killing the virus and
accelerating an antibody response
Memory cells
9. • COVID-19 vaccines induce neutralizing
antibodies against the spike protein
• When SARS-CoV-2 is encountered naturally,
neutralizing antibodies bind to the SARS-
CoV-2 spike protein and block the virus
from entering and multiplying in the cell
• A ‘weaker’ immune system (e.g. in elderly
people or those with underlying health
problems) may result in delayed and low
stimulation of the antibody response after
vaccination
• Current COVID 19 vaccines induce systemic
immunity only and no mucosal immunity
9
Vaccine-induced immunity to COVID-19
Antibodies to other
components may not
effectively neutralize
the virus
Antibodies that attach
differently may not
effectively neutralize
the virus
Neutralizing antibody
hypothesis: the antibody
changes the viral spike
protein and prevents entry of
the virus via the ACE2
receptor into a targeted cell
10. • Current intramuscular COVID-19 vaccines do not induce mucosal immunity. They do not
induce the same multifaceted immune response as a natural infection but do protect from
severe disease
• Nasal COVID-19 vaccines are being investigated to protect from infection as well as from
severe disease
10
Mucosal immunity may work as a barrier to infection
Infection-induced immunity induces systemic
immunity but also mucosal immunity because SARS-
CoV-2 infection starts in the upper respiratory tract
Vaccine-induced immunity induces systemic
immunity only and no mucosal immunity
11. • Neutralizing antibodies seem to correlate with
protection from symptomatic SARS-CoV-2
infection1,2
• Data suggest that antibodies against SARS-CoV-2
persist for at least 6 months after vaccination
• Waning of neutralizing antibodies has been
reported3. However, it is unclear if declining
antibody titers are indicative of declining
protection
• At present, it is unknown what level of neutralizing
antibodies or other immune markers are associated
with a vaccine’s protection of infection, severe
disease and transmission
11
Antibody based immunity after COVID-19 vaccination
1.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection | Nature Medicine
2. 2021.08.09.21261290v1.full.pdf (medrxiv.org)
3. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (nih.gov)
14. Alpha Beta Gamma Delta
Transmissibility Increased transmissibility Increased transmissibility Increased transmissibility Increased transmissibility.
Similar transmissibility
between vaccinated and
unvaccinated individuals
Disease severity Increased risk of
hospitalization, possible
increased risk of severity
and mortality
Not confirmed, possible
increased risk of in-hospital
mortality
Not confirmed, possible
increased risk of
hospitalization
Increased risk of
hospitalization
Risk of
reinfection
Neutralizing activity
retained
Reduction in neutralizing
activity reported
Moderate reduction in
neutralizing activity reported
Reduction in neutralizing
activity reported
Impact on
diagnostics
No impact on RTPCR or
Ag RDTs observed
No impact on RTPCR or Ag
RDTs observed
None reported to date None reported to date
Effectiveness of
COVID-19
vaccines
Protection retained Protection retained against
severe disease; reduced
protection against
symptomatic disease; limited
evidence
Unclear impact; very limited
evidence
Protection retained against
severe disease; possible
reduced protection against
symptomatic disease and
infection; limited evidence
14
COVID-19 vaccines are still effective to protect against
severe disease due to SARS-CoV-2 variants
https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021
Characteristics of global circulating SARS-CoV-2 variants of concern:
16. • Immunocompromised people may not respond sufficiently to two doses of COVID-19
vaccine. For example, in a trial with organ transplant recipients only 4% of people generated
SARS-CoV-2 antibodies after one dose, increasing to 40% after two doses and 68% after
three doses2
• Emerging data shows that immunocompromised people should receive a third dose if they
did not respond sufficiently to their initial doses or if they are no longer producing
antibodies. Such groups would be exempt from the booster moratorium2
16
Target groups for COVID-19 booster doses
1. WHO news updates
2. https://www.nejm.org/doi/full/10.1056/NEJMc2108861
Poor primary response to vaccination
• Third doses should be prioritized for the vulnerable: those most at-risk populations when
there is evidence of waning immunity against severe disease and death. They are not for the
fit and healthy1
Waning immunity
Interim statement on COVID-19 vaccine booster doses (who.int)
17. • COVID-19 vaccination in low-income countries
is lacking behind
• As of 3 September 2021, 5.4 billion vaccine
doses have been administered
• 40% of the world population has received at
least one dose of a COVID-19 vaccine
• Only 1.8% of people in low-income countries
have received at least one dose
17
Update on COVID-19 vaccine global distribution
https://ourworldindata.org/covid-vaccinations
18. • The COVAX Facility provides access
to COVID-19 vaccines to all
participating countries, regardless
of income levels
• As of 24 August 2021, COVAX has
shipped over 207 million COVID-19
vaccines to 138 participants
18
COVAX Facility provides access and deploys COVID-19 vaccines to
all participating countries
Photo: UNICEF
* https://www.gavi.org/vaccineswork/gavi-covax-amc-explained
19. • In the context of ongoing global vaccine supply constraints, administration of booster
doses will exacerbate inequities by driving up demand and consuming scarce supply
while priority populations in some countries, or subnational settings, have not yet
received a primary vaccination series
• The focus for the time being remains on increasing global vaccination coverage with
the primary series (either one or two doses for current EUL vaccines)
• However, if third doses are prioritized for those most at-risk while global access to
vaccines is increased - such as through increasing production and donating doses to
COVAX - then they should not be seen as depriving others of their first doses
19
Globally, many health workers and populations at risk have not yet had
their first or second vaccinations
Interim statement on COVID-19 vaccine booster doses (who.int)
WHO news updates
20. • Coronavirus (COVID-19) Vaccinations - Statistics and Research - Our World in Data
• COVAX (who.int)
• The Gavi COVAX AMC Explained | Gavi, the Vaccine Alliance
• Weekly epidemiological update on COVID-19 - 10 August 2021 (who.int)
• Interim statement on COVID-19 vaccine booster doses (who.int)
• WHO news updates
20
Resources
21. 21
COVID-19 protective measures
Protect yourself & others
Cough & sneeze into
your elbow
Wear a mask
Keep your distance Wash your hands
frequently
Ventilate or open
windows